Wednesday, 7 March 2012
The latest COVER report has been published which details the uptake of childhood vaccinations in Wales for the last quarter of 2011 (October-December) and which also includes uptake data for the non-routine BCG and hepatitis B vaccines.
These results are for children living in Wales in February 2012 and reaching their first, second, fifth, 15th and 16th birthdays during the quarter 01/10/2011 to 31/12/2011.
Uptake of HPV vaccination in girls in the 2011-12 School Year 8 (reaching their 13th birthday between 01/09/2011 and 31/08/2012) is presented, along with coverage in the previous year’s School Year 8 group. HPV vaccination protects girls against cervical cancer associated with HPV types 16 and 18. The routine HPV vaccination schedule consists of three doses, usually given to girls in school Year 8 at intervals of one to two months and then six months after the first dose.
BCG and hepatitis B immunisation uptake data are also presented here. BCG and hepatitis B immunisations are not part of the routine childhood schedule and are given selectively following risk assessment.
- Uptake of all scheduled immunisations in children less than one year of age exceeded the 95% uptake target this quarter. Twenty Local Authority (LA) areas exceeded the 95% uptake target for the 5 in 1 and MenC vaccines, with 17 achieving 95% uptake for all routine immunisations in one year olds.
- Uptake of the first dose of MMR vaccine in two year old children increased to 93% this quarter and ranged by LA from 89% to just below 97%. Eight LA area achieved the target of 95% uptake.
- Uptake of the second MMR dose by five years of age increased to 88% this quarter, ranging by LA from 82% to 92%.
- Uptake of 4 in 1 pre-school booster in five year old children was 90%, ranging by LA from 84% to 95%.
- Uptake of first dose of Human Papilloma Virus (HPV) vaccine in girls in the 2010-11 School Year 8 was 88% and uptake of the complete three dose course was 84%.
- Coverage of one dose of MMR vaccine in 16 year olds this quarter was 92% and coverage of a completed two dose course was 83%.